Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Plans Major Investment In All Drug Making Aspects In China

This article was originally published in PharmAsia News

Executive Summary

Swiss drug maker Novartis plans a major investment in China covering all aspects of selling pharmaceuticals in the country. Part of the planned investment includes greater emphasis on recruiting staff as its Chinese facilities expand, in part to launch six new drugs and conduct clinical trials this year. The CEO of Novartis Pharmaceuticals Division, Joseph Jimenez, said the company was continuing to put more money into its research and development center in Shanghai. Jimenez declined to set a figure on the investment, but said it would be considerable. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts